Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet...

Full description

Bibliographic Details
Main Authors: Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Current Oncology
Subjects:
lorlatinib
non-small cell lung cancer
real-world evidence
quality-of-life
effectiveness
second line
Online Access:https://www.mdpi.com/1718-7729/30/7/481

Internet

https://www.mdpi.com/1718-7729/30/7/481

Similar Items